|
WO1994022846A1
(en)
|
1993-03-30 |
1994-10-13 |
Pfizer Inc. |
Compounds enhancing antitumor activity of other cytotoxic agents
|
|
EP0721328A4
(en)
|
1993-09-27 |
1997-09-17 |
Smithkline Beecham Corp |
CAMPTOTHECIN FORMULATIONS
|
|
US5786344A
(en)
|
1994-07-05 |
1998-07-28 |
Arch Development Corporation |
Camptothecin drug combinations and methods with reduced side effects
|
|
US5919816A
(en)
*
|
1994-11-14 |
1999-07-06 |
Bionumerik Pharmaceuticals, Inc. |
Formulations and methods of reducing toxicity of antineoplastic agents
|
|
US5972614A
(en)
*
|
1995-12-06 |
1999-10-26 |
Genaissance Pharmaceuticals |
Genome anthologies for harvesting gene variants
|
|
DE69734237T2
(de)
|
1996-03-01 |
2006-07-06 |
The University Court Of The University Of Dundee, Dundee |
Versuchsystem für einen Arzneimittelversuch
|
|
US6287834B1
(en)
*
|
1996-05-17 |
2001-09-11 |
Endorecherche, Inc. |
Characterization and use of an isolated uridine diphospho-glucuronosyltransferase
|
|
DE19744676A1
(de)
|
1997-10-10 |
1999-04-15 |
Forschungszentrum Borstel Zent |
Kombinationspräparate für die Therapie von Tumoren
|
|
WO1999057322A2
(en)
|
1998-05-07 |
1999-11-11 |
Axys Pharmaceuticals, Inc. |
Genotyping the human udp-glucuronosyltransferase 1 (ugt1) gene
|
|
US6448003B1
(en)
*
|
1998-06-10 |
2002-09-10 |
Dna Sciences Laboratories, Inc. |
Genotyping the human phenol sulfotransferbase 2 gene STP2
|
|
US6407117B1
(en)
*
|
1998-06-18 |
2002-06-18 |
The George Washington University |
Method of administering camptothecin compounds for the treatment of cancer with reduced side effects
|
|
US6319678B1
(en)
*
|
1998-06-26 |
2001-11-20 |
Panvera Corporation |
Process for glucuronidation screening
|
|
US6586175B1
(en)
*
|
1998-07-28 |
2003-07-01 |
Dna Sciences Laboratories, Inc. |
Genotyping the human UDP-glucuronosyltransferase 2B7 (UGT2B7) gene
|
|
US6395481B1
(en)
*
|
1999-02-16 |
2002-05-28 |
Arch Development Corp. |
Methods for detection of promoter polymorphism in a UGT gene promoter
|
|
AU2001255397A1
(en)
|
2000-04-18 |
2001-10-30 |
Genaissance Pharmaceuticals, Inc. |
Haplotypes of the ugt1a1 gene
|
|
EP1325152A2
(en)
|
2000-07-14 |
2003-07-09 |
F. Hoffmann-La Roche Ag |
Method for detecting pre-disposition to hepatotoxicity
|
|
AU2002245039A1
(en)
|
2000-11-28 |
2002-07-30 |
Dna Sciences Laboratories, Inc. |
Genetic typing of human genes and related materials and methods
|
|
EP1352970B1
(en)
|
2000-12-12 |
2010-06-02 |
Nagoya Industrial Science Research Institute |
Method of estimating the risk of expression of adverse drug reaction caused by the administration of a compound, which is either metabloized per se by ugt1a1 or whose intermediate is metabolized by the enzyme
|
|
DE10100238A1
(de)
*
|
2001-01-05 |
2002-08-22 |
Hannover Med Hochschule |
Verfahren zur Vorhersage des Gefährdungspotentials für Karzinomerkrankungen und entzündliche Darmerkrankungen und zugehörige Tests
|
|
WO2002059375A2
(en)
*
|
2001-01-26 |
2002-08-01 |
University Of Chicago |
Determination of ugt2b7 gene polymorphisms for predicting ugt2b7 substrate toxicity and for optimising drug dosage
|
|
WO2003013534A2
(en)
|
2001-07-23 |
2003-02-20 |
Epidauros Biotechnologie Ag |
Methods for the treatment of cancer with irinotecan based on cyp3a5
|
|
JP4096037B2
(ja)
|
2002-08-12 |
2008-06-04 |
国立大学法人滋賀医科大学 |
グルクロン酸転移酵素遺伝子の変異解析による薬剤代謝活性の予測方法
|
|
US20040203034A1
(en)
*
|
2003-01-03 |
2004-10-14 |
The University Of Chicago |
Optimization of cancer treatment with irinotecan
|